Samsung Biologics (KRX:207940) said its Switzerland-based unit, Samsung Peptide, has published the prospectus for its public tender offer for PolyPeptide Group, according to a Monday release.
The offer includes 44.31 Swiss francs in cash per PolyPeptide share, implying an equity value of about 1.46 billion francs, and represents a 40% premium to the unaffected share price.
The offer is expected to run between Sept. 15 and Oct. 12, subject to a minimum acceptance threshold, and the largest individual shareholder, Draupnir Holding, with about a 55.65% stake, has committed to tendering all its shares.